Current Neuro-Oncology

Volume 27 Number 24
31 August 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 24, 31 August

Scheu K, Vandieken E, Hense K, Rosengarth K, Haedenkamp T, Lenglinger M, Bumes E, Linker R, Proescholdt M, Schmidt NO, Riemenschneider MJ, Wendl C, Wiesinger I, Hau P.
MRI-defined patterns of infiltration and outcome in patients with glioblastoma.
Neurooncol Adv. 2025 Jul 10;7(1):vdaf114. doi: 10.1093/noajnl/vdaf114. PMID: 40842643. Observational study. ˍ

Whittle JR, Vieito M, Rohrberg K, Rodriguez-Ruiz ME, Castanon E, Mellinghoff IK, Van Linde M, Cloughesy T, Reardon DA, Chong RA, Rosenthal M, Wick A, Waldhauer I, Henkel N, Romagnoli B, Wolowski V, Dey S, Heil F, Heichinger C, Flinn N, Gou JP, Smith L, Prince F, Derks M, Roller A, Schiff C, Schneider M, Mason W.
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
Neurooncol Adv. 2025 Jul 18;7(1):vdaf160. doi: 10.1093/noajnl/vdaf160. PMID: 40842640. Interventional study. ˍ ClinicalTrial.gov ID: NCT05187624.

Ferles A, Majewska P, Holden Helland R, Kommers I, Pedersen A, Tranfa M, Ardon H, Bello L, Berger MS, Dunås T, Nibali MC, Furtner J, Hervey-Jumper SL, Idema AJS, Kiesel B, Tewarie RN, Mandonnet E, Robe PA, Rossi M, Sciortino T, Aalders T, Wagemakers M, Widhalm G, Zwinderman AH, Sagberg LM, Jakola AS, Thurin E, Reinertsen I, Bouget D, Solheim O, Eijgelaar RS, de Witt Hamer PC, Barkhof F.
Estimating overall survival of glioblastoma patients using clinical variables, tumor size, and location.
Neurooncol Adv. 2025 Aug 3;7(1):vdaf154. doi: 10.1093/noajnl/vdaf154. PMID: 40842642. Observational study. ˍ

Liu Y, Ma L, Fu X, Zhang Y, Zheng J, Chen Z.
Safety assessment of temozolomidee: real-world adverse event analysis from the FAERS database.
Front Pharmacol. 2025 Aug 6;16:1578406. doi: 10.3389/fphar.2025.1578406. PMID: 40843381. Observational study. ˍ

Tan PK, Martins TJ, Becker PS, Wechsler-Reya RJ, Crawford JR.
Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.
Front Oncol. 2025 Aug 7;15:1606575. doi: 10.3389/fonc.2025.1606575. PMID: 40852486. Case report. ˍ

Depond CC, Jecko V, Weller J, Tuppin P, Metellus P.
Overall survival after carmustine wafers implantation for newly-diagnosed high grade glioma. A nationwide population-based controlled propensity score-matched analysis.
Clin Neurol Neurosurg. 2025 Aug 12;257:109081. doi: 10.1016/j.clineuro.2025.109081. PMID: 40848613. Observational study˰ ˍ

Jacobsen J, Locallo A, O'Rourke CJ, Carlsen JF, Cohen J, Ewald JD, Scheie D, Grunnet K, Schmidt AY, Melchior LC, Larsen VA, Andersen JB, Poulsen HS, Weischenfeldt J, Broholm H, Michaelsen SR, Kristensen BW.
Clinical, Radiological, and Molecular Insights into Extracranial Metastases from Adult Gliomas.
Neuro Oncol. 2025 Aug 16:noaf178. doi: 10.1093/neuonc/noaf178. PMID: 40842361. Observational study. ˍ

Yogendran LV, Kareddy A, Abbas SO, Scharf Z, Patrie J, Patel SH, Schiff D.
Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression.
J Neurooncol. 2025 Aug 20. doi: 10.1007/s11060-025-05087-w. PMID: 40836201. Observational study. ˍ

Drummond KJ, Spiteri M, Cain SA, Jones J, Shaya S, Topp M, Lu T, Tobler R, Valkovic AL, Moore Z, Fatunla OE, Kriel J, Moffet JJD, McAlpine H, Rosier M, Guan H, Dimou J, Schadewaldt V, Roberts-Thomson S, McArdle D, Lui E, Voelker-Albert M, di Sanzo S, Nijagal B, Narayana VK, Mitchell CB, Vissers JHA, Grimmond S, Rosenthal MA, Palmer LM, Best SA, Freytag S, Whittle JR.
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial.
Nat Med. 2025 Aug 21. doi: 10.1038/s41591-025-03884-4. PMID: 40841487. Interventional study. ˍ ClinicalTrials.gov ID: NCT05577416.

Kang Z, Li S, Wang L, Chen Q, Hu W, Lei T, Mao Y, Zhang J, Xiang X, Wang Q, He Z, Sun T, Wang Y, Huang M, Zhang R, Chen F, Li W.
SYHA1813, A VEGFR and CSF1R Inhibitor, in Patients With Recurrent High-Grade Gliomas: A Multicenter, Open-Label Phase I Study.
Ann Clin Transl Neurol. 2025 Aug 22. doi: 10.1002/acn3.70166. PMID: 40847460. Interventional study. ˍ ChiCTR.org.cn ID: ChiCTR2100045380.